Affichem selected for the 2014 UBIStart program.

Affichem selected for the 2014 UBIStart program.

A prestigious selection and unique experience in New-York for Affichem selected by the very popular UBISTART 2014 program.
BIO 2014 - San Diego, CA

BIO 2014 - San Diego, CA

AFFICHEM will be present at San Diego this year to celebrate the 2014 edition of the world's largest event for the biotechnology industry, BIO, which takes place from 23 to 26 June 2014.
Science publication

Science publication

Cholesterol metabolites can promote or suppress breast cancer.
Nature Communications publication

Nature Communications publication

The joint research between Affichem and the INSERM UMR1037 team co-led by Dr. Marc & Sandrine Poirot has led to the characterization of the Dendrogenin A as the first steroidal alkaloid identified in humans.
Affichem captures the listening of the European Union

Affichem captures the listening of the European Union

Affichem focuses on the development of a revolutionary drug against deafness through an EU grant of € 2.8 million obtained in September 2012.
NCE - Biomarker - Drug design - Anticancer therapy - Cell differentiation - Receptor - Enzyme - Metabolism - Cancer - Deafness - Deafness - Melanoma - Neurodegenerative disease - Medicinal chemistry - Biotechnology - First in class molecule - New Chemical Entities - Cholesterol - Tamoxifen - Immunotherapy - Exosome - Oncology - Dendritic cell - Theranostic - Diagnosis - Prognosis -